Furthermore, serum MXRA5 concentrations, in conjunction with the presence of perianal lesions, may act as valuable predictors of endoscopic response to IFX, thereby offering potential clinical utility in the development of personalized treatment strategies for CD. The gene discussed is MXRA5; the disease is Cowden disease.